Hydroxychloroquine, and old acquaintance that gained strength in the pandemic.

By : Global Rheumatology by PANLAR
18 September, 2020
https://doi.org/10.46856/grp.232.e041
views 535Views

License

This is an open-access article distributed by the terms of the Creative Common Attribution License (CC-BY NC-4). The use, distribution or reproduction in other forms is permitted, provided the original author(a) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with this terms.

As of December 2019, the COVID-19 epidemic represented one of the major therapeutic challenges faced to date, even more so when the use of medicines that were already known and perhaps forgotten by most of the medical community, but which were part of the rheumatologist's daily routine, was proposed. Specifically, we have witnessed the evolution on the evidence regarding the usefulness or not of an old acquaintance, Hydroxychloroquine. 

 

We want to know the perspectives of different specialists and analyze this therapeutic phenomenon, for that reason we are accompanied by Dr. Guillermo Pons, Research Rheumatologist at the Regional Center of Autoimmune and Rheumatic Diseases of Grupo Oroño in Rosario, Argentina (in Spanish, Centro Regional de Enfermedades Autoinmunes y Reumáticas), with extensive experience in the management of antimalarials, Julio Cesar García-Casallas, Director of the Medicine Program at the Sabana University in Chía, Colombia, Internist Clinical Pharmacologist and Hector Posso, Professor in the Department of Epidemiology at the Sabana University in Chía, Colombia, Epidemiologist, PhD in public health, with extensive experience in the design and monitoring of clinical trials that together with our host, Dr. Diego Jaimes and our editor Carlo Vinicio Caballero will analyze this topic of great interest in our specialty.

 

enviar Envía un artículo